Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 24, 2026, 5:14 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 721–744 of 5,775 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Bronchial Disease Clear all
Completed Phase 3 Interventional

Coaching in Childhood Asthma

NCT00910585
View directory record Official record
Conditions
Asthma
Interventions
Coaching, providing social support
Behavioral
Lead sponsor
Washington University School of Medicine
Other
Eligibility
Not listed
Enrollment
191 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1997 – 2002
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Jun 1, 2009 · Synced Oct 24, 2026, 5:14 PM EDT
Not listed Phase 2 Interventional

T138067 in Treating Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer That Has Not Responded to Previous Chemotherapy

NCT00022243
View directory record Official record
Conditions
Lung Cancer
Interventions
batabulin sodium
Drug
Lead sponsor
Tularik
Industry
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2000
U.S. locations
2
States / cities
San Francisco, California • Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Jan 6, 2014 · Synced Oct 24, 2026, 5:14 PM EDT
Completed Phase 2 Interventional Results available

A Phase 2a Study to Evaluate the Safety and Tolerability of Benralizumab (MEDI-563) in Adults With Asthma

NCT00783289
View directory record Official record
Conditions
Asthma
Interventions
Placebo, Benralizumab 25 mg, Benralizumab 100 mg, Benralizumab 200 mg
Other · Biological
Lead sponsor
MedImmune LLC
Industry
Eligibility
18 Years to 80 Years
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
6
States / cities
Encinitas, California • Los Angeles, California • Colorado Springs, Colorado + 3 more
Source: ClinicalTrials.gov public record
Updated Dec 27, 2019 · Synced Oct 24, 2026, 5:14 PM EDT
Completed Phase 1Phase 2 Interventional

A Phase 1/2 Study of CYT-0851 in B-Cell Malignancies and Advanced Solid Tumors

NCT03997968
View directory record Official record
Conditions
Malignancy, Non-hodgkin Lymphoma, Multiple Myeloma, Breast Cancer, Ovarian Cancer, Soft Tissue Sarcoma, Head and Neck Cancer, DLBCL, Mantle Cell Lymphoma, Follicular Lymphoma, Pancreatic Cancer, CLL, Small Cell Lung Cancer, Squamous Cell Carcinoma of Head and Neck, Triple Negative Breast Cancer
Interventions
CYT-0851, CYT-0851 in combination with gemcitabine, CYT-0851 in combination with capecitabine, CYT-0851 in combination with rituximab and bendamustine
Drug
Lead sponsor
Cyteir Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
169 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2024
U.S. locations
16
States / cities
San Francisco, California • Stanford, California • Denver, Colorado + 12 more
Source: ClinicalTrials.gov public record
Updated Dec 24, 2024 · Synced Oct 24, 2026, 5:14 PM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

Examining Bronchial Hyperresponsiveness in Primary Ciliary Dyskinesia

NCT07288827
View directory record Official record
Conditions
Primary Ciliary Dyskinesia, Healthy
Interventions
Lung Function Testing, Phlebotomy, Allergy skin prick testing, Methacholine Challenge
Procedure
Lead sponsor
Indiana University
Other
Eligibility
6 Years and older
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2028
U.S. locations
1
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Dec 17, 2025 · Synced Oct 24, 2026, 5:14 PM EDT
Completed Early Phase 1 Interventional Accepts healthy volunteers Results available

GSNOR Phenotyping/GSNO Challenge in Severe Asthma

NCT03926741
View directory record Official record
Conditions
Asthma
Interventions
GSNO Challenge
Drug
Lead sponsor
James Reynolds
Other
Eligibility
18 Years to 50 Years
Enrollment
48 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2024
U.S. locations
2
States / cities
Indianapolis, Indiana • Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated May 20, 2026 · Synced Oct 24, 2026, 5:14 PM EDT
Terminated Phase 1 Interventional

Immune Checkpoint Inhibition With Lurbinectedin Relapsed/Recurrent SCLC

NCT04610658
View directory record Official record
Conditions
Small-cell Lung Cancer, Relapsed Small Cell Lung Cancer, Recurrent Small Cell Lung Cancer
Interventions
Nivolumab, Ipilimumab, Lurbinectedin
Drug
Lead sponsor
H. Lee Moffitt Cancer Center and Research Institute
Other
Eligibility
18 Years and older
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
2
States / cities
Kissimmee, Florida • Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Apr 2, 2024 · Synced Oct 24, 2026, 5:14 PM EDT
Not listed No phase listed Observational

Measuring Omalizumab Responses Using Real-world Evidence (MORRE) Study

NCT04724278
View directory record Official record
Conditions
Asthma
Interventions
Not listed
Lead sponsor
National Jewish Health
Other
Eligibility
18 Years to 85 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
1
States / cities
Denver, Colorado
Source: ClinicalTrials.gov public record
Updated Jun 23, 2021 · Synced Oct 24, 2026, 5:14 PM EDT
Active, not recruiting Phase 2 Interventional Results available

Pembrolizumab Every 12 Weeks Versus Every 3 Weeks in Treating Patients With Non-small Cell Lung Cancer

NCT04032418
View directory record Official record
Conditions
Lung Non-Small Cell Carcinoma
Interventions
Pembrolizumab
Biological
Lead sponsor
Roswell Park Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2026
U.S. locations
1
States / cities
Buffalo, New York
Source: ClinicalTrials.gov public record
Updated Oct 22, 2026 · Synced Oct 24, 2026, 5:14 PM EDT
Completed Phase 3 Interventional

A Trial of Carboplatin and Gemcitabine Versus Gemcitabine Alone in Patients With Non-Small-Cell Lung Cancer

NCT00190710
View directory record Official record
Conditions
Non-Small Cell Lung Cancer
Interventions
Gemcitabine, Carboplatin
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
Enrollment
242 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2007
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Nov 14, 2007 · Synced Oct 24, 2026, 5:14 PM EDT
Completed Phase 2 Interventional Results available

A Randomized Study To Evaluate The Efficacy And Safety Of An Investigational Drug In Adolescent And Adult Subjects With Asthma Uncontrolled on Non-steroidal Therapy.

NCT00603382
View directory record Official record
Conditions
Asthma
Interventions
GW685698X, Placebo
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
12 Years and older
Enrollment
599 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
94
States / cities
Phoenix, Arizona • Fort Smith, Arkansas • Little Rock, Arkansas + 81 more
Source: ClinicalTrials.gov public record
Updated Apr 18, 2018 · Synced Oct 24, 2026, 5:14 PM EDT
Completed Phase 2 Interventional Results available

Symptom Clusters in Children With Exacerbation-prone Asthma

NCT04002362
View directory record Official record
Conditions
Asthma in Children
Interventions
Triamcinolone Acetonide
Drug
Lead sponsor
Emory University
Other
Eligibility
6 Years to 21 Years
Enrollment
68 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2025
U.S. locations
2
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Feb 13, 2026 · Synced Oct 24, 2026, 5:14 PM EDT
Completed Phase 2 Interventional

A Pilot Study to Evaluate the ROX Anastomotic Coupler System in Patients With Chronic Obstructive Pulmonary Disease

NCT00992680
View directory record Official record
Conditions
Chronic Obstructive Pulmonary Disease
Interventions
ROX Anastomotic Coupler System (ACS)
Device
Lead sponsor
ROX Medical, Inc.
Industry
Eligibility
18 Years to 80 Years
Enrollment
49 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2013
U.S. locations
9
States / cities
Phoenix, Arizona • Los Angeles, California • Orlando, Florida + 5 more
Source: ClinicalTrials.gov public record
Updated Apr 21, 2014 · Synced Oct 24, 2026, 5:14 PM EDT
Completed Phase 4 Interventional Results available

A Clinical Study to Evaluate the Effect of the Connected Inhaler System (CIS) on Adherence to Maintenance Therapy in Poorly Controlled Asthmatic Subjects

NCT03380429
View directory record Official record
Conditions
Asthma
Interventions
RELVAR/BREO, Salbutamol, Smart phone app, HCP Dashboard, Sensors
Drug · Device
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years and older
Enrollment
437 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
11
States / cities
Aventura, Florida • Miami, Florida • Flossmoor, Illinois + 8 more
Source: ClinicalTrials.gov public record
Updated Apr 12, 2021 · Synced Oct 24, 2026, 5:14 PM EDT
Completed Phase 1Phase 2 Interventional Results available

A Study of INCAGN01876 in Participants With Advanced or Metastatic Solid Tumors

NCT02697591
View directory record Official record
Conditions
Advanced Malignancies, Metastatic Cancer
Interventions
INCAGN01876
Drug
Lead sponsor
Incyte Biosciences International Sàrl
Industry
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
8
States / cities
Los Angeles, California • New Haven, Connecticut • Boston, Massachusetts + 4 more
Source: ClinicalTrials.gov public record
Updated Feb 26, 2021 · Synced Oct 24, 2026, 5:14 PM EDT
Active, not recruiting Phase 1Phase 2 Interventional Results available

UCDCC#272: IL-2, Radiotherapy, and Pembrolizumab in Patients Refractory to Checkpoint Blockade

NCT03474497
View directory record Official record
Conditions
Non Small Cell Lung Cancer, Metastatic Melanoma, Metastatic Renal Cell Carcinoma, Head and Neck Squamous Cell Carcinoma
Interventions
IL-2, Pembrolizumab, Radiotherapy
Drug · Radiation
Lead sponsor
Megan Daly, MD
Other
Eligibility
18 Years and older
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2026
U.S. locations
2
States / cities
Sacramento, California
Source: ClinicalTrials.gov public record
Updated Jan 29, 2026 · Synced Oct 24, 2026, 5:14 PM EDT
Completed Not applicable Interventional

Effectiveness of Influenza Vaccine Reminder Systems

NCT01852656
View directory record Official record
Conditions
Asthma, Chronic Obstructive Pulmonary Disease
Interventions
Postcard and IVR Reminder Group, Postcard Only Reminder Group, IVR Only Reminder Group
Behavioral
Lead sponsor
Kaiser Permanente
Other
Eligibility
19 Years to 64 Years
Enrollment
12,255 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
1
States / cities
Denver, Colorado
Source: ClinicalTrials.gov public record
Updated May 14, 2013 · Synced Oct 24, 2026, 5:14 PM EDT
Completed Phase 1 Interventional

Chemotherapy, Tirapazamine, and Radiation Therapy in Treating Patients With Non-Small Cell Lung Cancer

NCT00033410
View directory record Official record
Conditions
Lung Cancer
Interventions
carboplatin, paclitaxel, tirapazamine, radiation therapy
Drug · Radiation
Lead sponsor
California Cancer Consortium
Network
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2002
U.S. locations
2
States / cities
Duarte, California • Sacramento, California
Source: ClinicalTrials.gov public record
Updated Feb 9, 2009 · Synced Oct 24, 2026, 5:14 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

World Trade Center Adolescent Health Study

NCT02068183
View directory record Official record
Conditions
Asthma, Hypertension, Cardiovascular Risk Factor, Insulin Resistance, Stress Disorders, Post-Traumatic, Exposure to Toxic Dust
Interventions
Not listed
Lead sponsor
NYU Langone Health
Other
Eligibility
12 Years to 20 Years
Enrollment
402 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2016
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jan 24, 2017 · Synced Oct 24, 2026, 5:14 PM EDT
Active, not recruiting Phase 1 Interventional

Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 as Monotherapy and in Combination With IV Bevacizumab

NCT05029882
View directory record Official record
Conditions
Non-Small Cell Lung Cancer, Advanced Solid Tumors, Gastroesophageal Adenocarcinoma, Colorectal Cancer
Interventions
ABBV-400, Trifluridine/Tipiracil, Bevacizumab
Drug
Lead sponsor
AbbVie
Industry
Eligibility
18 Years and older
Enrollment
520 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
18
States / cities
Los Angeles, California • Aurora, Colorado • New Haven, Connecticut + 13 more
Source: ClinicalTrials.gov public record
Updated Oct 29, 2025 · Synced Oct 24, 2026, 5:14 PM EDT
Active, not recruiting Phase 1 Interventional

Radiotherapy and Durvalumab/Durvalumab Combo (Tremelimumab/Olaparid) for Small Cell Lung Cancer

NCT03923270
View directory record Official record
Conditions
Small Cell Lung Cancer Extensive Stage, Small-cell Lung Cancer
Interventions
Durvalumab, Tremelimumab, Olaparib Pill, Thoracic Radiotherapy
Drug · Radiation
Lead sponsor
H. Lee Moffitt Cancer Center and Research Institute
Other
Eligibility
18 Years and older
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2026
U.S. locations
1
States / cities
Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Apr 1, 2026 · Synced Oct 24, 2026, 5:14 PM EDT
Completed Phase 1 Interventional

Phase I Vorinostat Concurrent With Stereotactic Radiosurgery (SRS) in Brain Metastases From Non-Small Cell Lung Cancer

NCT00946673
View directory record Official record
Conditions
Brain Cancer, Neoplasm Metastasis, Lung Cancer, Carcinoma, Non-Small-Cell Lung
Interventions
Vorinostat, Radiation Therapy
Drug · Procedure
Lead sponsor
Stanford University
Other
Eligibility
18 Years and older
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2015
U.S. locations
2
States / cities
Stanford, California • Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Oct 6, 2017 · Synced Oct 24, 2026, 5:14 PM EDT
Completed Phase 2 Interventional

Improving Asthma Communication in Minority Families

NCT00133666
View directory record Official record
Conditions
Asthma
Interventions
Asthma Communication Education, Standard Asthma Education
Behavioral
Lead sponsor
National Institute of Nursing Research (NINR)
NIH
Eligibility
6 Years to 12 Years
Enrollment
231 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2008
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 17, 2008 · Synced Oct 24, 2026, 5:14 PM EDT
Completed Not applicable Interventional

Feasibility of a Hepatitis C Virus (HCV) Decision-Making Intervention Among HIV-infected Adults

NCT01472354
View directory record Official record
Conditions
Hepatitis c
Interventions
Leap-c group intervention
Behavioral
Lead sponsor
University of Massachusetts, Worcester
Other
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
1
States / cities
Worcester, Massachusetts
Source: ClinicalTrials.gov public record
Updated May 30, 2013 · Synced Oct 24, 2026, 5:14 PM EDT